Denali Therapeutics
DNLI
188 hedge funds and large institutions have $2.73B invested in Denali Therapeutics in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 72 increasing their positions, 58 reducing their positions, and 19 closing their positions.
224% more call options, than puts
Call options by funds: $1.82M | Put options by funds: $561K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
24% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 58
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
4.75% more ownership
Funds ownership: 70.64% → 75.39% (+4.7%)
3% less capital invested
Capital invested by funds: $2.8B → $2.73B (-$71.3M)
1% less funds holding
Funds holding: 190 → 188 (-2)
Top Buyers
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
+$135M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$17.4M |
| 3 |
Millennium Management
New York
|
+$16.9M |
| 4 |
BlackRock
New York
|
+$15.7M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$13.1M |
Top Sellers
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$17.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$11.7M |
| 3 |
BAMCO Inc
New York
|
-$9.94M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.21M |
| 5 |
Morgan Stanley
New York
|
-$7.4M |
DNLI Hedge Fund Activity: Q2 2022 in Review
188 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q2 2022, worth a combined $2.73B — down 2.5% from $2.8B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new DNLI positions and 19 closed out — a net gain of 2 holders — while 72 added to existing stakes and 58 trimmed.
The largest buyer was Arch Venture Management, opening a new position worth an estimated $135M. The largest seller was Gilder Gagnon Howe & Co, cutting an estimated $17.4M.
- 188 institutional investors held Denali Therapeutics (DNLI) as of Q2 2022, down from 190 in Q1 2022.
- Funds reported $2.73B of Denali Therapeutics stock for Q2 2022, down 2.5% quarter-over-quarter.
- 21 funds opened new Denali Therapeutics positions in Q2 2022 and 19 closed out, a net change of +2 holders.
- The largest Denali Therapeutics buyer in Q2 2022 was Arch Venture Management, an estimated $135M added.
- The largest Denali Therapeutics seller in Q2 2022 was Gilder Gagnon Howe & Co, an estimated $17.4M sold.
Based on aggregated 13F filings for Q2 2022.